The rationale for sentinel-node biopsy in primary melanoma

Article metrics

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Thomas JM (2008) Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5: 18–23

  2. 2

    Rosenberg SA (2008) Why perform sentinel-lymph-node biopsy in patients with melanoma? Nat Clin Pract Oncol 5: 1

  3. 3

    Morton DL et al. (2005) Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242: 302–311

  4. 4

    Morton DL et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307–1317

  5. 5

    Morton DL and the MSLT-II Trials Group. Interim update of MSLT-I and MSLT-II. Sixth Biennial International Sentinel Node Society Meeting, Sydney, Australia, 18–20 February 2008

  6. 6

    Balch CM et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622–3634

  7. 7

    Morton DL et al. (2007) Sentinel-node biopsy in melanoma. N Engl J Med 356: 419–420

  8. 8

    Morton DL et al. (2007) Can completion lymph node dissection be avoided for a positive sentinel node in melanoma? Ann Surg Oncol 14: 2437–2439

  9. 9

    Balch CM and Cascinelli N (2007) Sentinel-node biopsy in melanoma. N Engl J Med 356: 420–421

  10. 10

    Sabel MS et al. (2007) Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 141: 728–735

  11. 11

    Starritt EC et al. (2005) Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 12: 18–23

  12. 12

    Wen D-R. et al. (2008) Tumor burden and outcome. Sixth Biennial International Sentinel Node Society Meeting, Sydney, Australia, 18–20 February 2008

  13. 13

    Scheri RP et al. (2007) Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14: 2861–2866

Download references

Acknowledgements

The Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) mentioned in this report are supported by funding from the National Cancer Institute (CA29605).

Author information

Correspondence to Donald L Morton.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Further reading